抗肿瘤治疗与心房颤动

Anti-tumor therapy and atrial fibrillation

心房颤动(房颤)是最常见的心律失常之一。近年来许多研究表明肿瘤和房颤有很多共同的危险因素,肿瘤的进展和抗肿瘤治疗都会增加房颤发生风险,抗肿瘤治疗过程中及随访中发生房颤事件会影响肿瘤患者的治疗效果和预后。肿瘤导致房颤可能与肿瘤相关治疗引起的心脏毒性作用相关,增加了肿瘤患者的死亡率。本文通过对国内外文献报道进行归纳总结,主要阐述肿瘤导致房颤的潜在机制。

Atrial fibrillation is one of the most common arrhythmias. A large number of studies have shown that tumor and atrial fibrillation share many common risk factors. Tumor progression and anti-tumor therapy can both increase the risk of atrial fibrillation,and the occurrence of atrial fibrillation event during anti-tumor therapy and follow-up can affect the treatment effect and prognosis of tumor patients. Tumor-induced atrial fibrillation may be related to the cardiotoxicity of tumor-associated therapy,increasing the mortality of tumor patients. This paper summarizes a large number of domestic and foreign literatures on the potential mechanism of tumor-induced atrial fibrillation.